Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Recon Technology regains Nasdaq compliance with $1 minimum bid price rule

Recon Technology regains Nasdaq compliance with $1 minimum bid price rule

BitgetBitget2026/09/18 12:30
  • Recon Technology regained compliance with Nasdaq’s $1 minimum bid requirement, ending a delisting risk tied to Listing Rule 5550(a)(2).
  • Nasdaq confirmed the stock’s closing bid stayed at or above $1 for 10 straight sessions from Sept. 1 to Sept. 15.
  • The company had received a Nasdaq deficiency notice on May 4 for trading below $1 for 30 consecutive business days.
  • Nasdaq closed the matter in a Sept. 16 letter, stating Recon is now compliant with all listing standards.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Recon Technology Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609180830PR_NEWS_USPR_____CN51275) on September 18, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

After Eli Lilly's nearly 300% surge in four years, Wall Street remains bullish: The "hidden pipeline" beyond GLP-1 is underestimated

Eli Lilly’s share price has surged nearly 300% since the approval of its first GLP-1 drug, with its market capitalization surpassing 1 trillion USD, yet Wall Street remains optimistic about its continued growth. Berenberg has upgraded Eli Lilly’s rating to “Buy," believing that Mounjaro and Zepbound will continue to see strong volume, and that the oral GLP-1 drug could further drive demand. Additionally, Eli Lilly continues to expand into areas such as cancer and sleep disorders, and the potential of its non-obesity-related pipelines remains underestimated by the market.

华尔街见闻2026/09/18 13:21

Goldman Sachs: The industrial sector is "even more expensive" than tech stocks; global sector pricing logic is changing

The 12-month forward price-to-earnings ratio of the industrial sector has now surpassed that of the technology sector, indicating that the relative valuations among various sectors in global stock markets are undergoing a shift.

智通财经2026/09/18 13:11